Method of efficiently establishing induced pluripotent stem cells

US10077429B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10077429-B2
Application numberUS-201314438106-A
CountryUS
Kind codeB2
Filing dateOct 23, 2013
Priority dateOct 23, 2012
Publication dateSep 18, 2018
Grant dateSep 18, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides a method of improving iPS cell establishment efficiency, comprising contacting a protein involved in primitive streak (PrS) formation, preferably Foxh1, or a nucleic acid that encodes the same with a somatic cell in a nuclear reprogramming step. Also provided is a method of producing an iPS cell, comprising contacting the protein involved in PrS formation or a nucleic acid that encodes the same, and nuclear reprogramming substance(s) with a somatic cell.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of improving induced pluripotent stem (iPS) cell establishment efficiency, comprising contacting a protein involved in primitive streak (PrS) formation or a nucleic acid that encodes the same with a somatic cell in vitro in a nuclear reprogramming step, wherein the protein is selected from the group consisting of forkhead box protein h1 (Foxh1), brachyury, Lin-11/Isl-1/Mec-3 homeobox protein 1 (LHX1), forkhead box protein b1 (Foxb1), forkhead box protein f1 (Foxf1), forkhead box protein f2 (Foxf2), and forkhead box protein g1 (Foxg1), and wherein the nuclear reprogramming step is performed by introducing nuclear reprogramming substances into the somatic cell, wherein the nuclear reprogramming substances comprise any of the following (a) to (d): (a) Oct3/4, Sox2, and Klf4, (b) (i) Oct3/4, (ii) a member of the Sox family selected from the group consisting of Sox1, Sox2, Sox3, Sox15, Sox17, and Sox18, (iii) a member of the Klf family selected from the group consisting of Klf1, Klf2, Klf4, and Klf5, and (iv) a member of the Myc family selected from the group consisting of c-Myc, L-Myc, and n-Myc, (c) Oct3/4, Sox2, Nanog, and Lin28, and (d) nucleic acids that encode any of (a) to (c), wherein (a) to (c) are proteins, thereby improving iPS cell establishment efficiency compared to that obtained by introducing the nuclear reprogramming substances alone into the somatic cell. 2. The method according to claim 1 , wherein the protein is Foxh1. 3. The method according to claim 1 , wherein the somatic cell is further contacted with Glioma-associated oncogene-similar 1 (Glis1) or a nucleic acid that encodes the same and/or a p53 inhibitor in vitro in the nuclear reprogramming step. 4. The method according to claim 1 , wherein the protein is brachyury. 5. The method according to claim 1 , wherein the protein is LHX1. 6. The method according to claim 1 , wherein the protein is Foxb1. 7. The method according to claim 1 , wherein the protein is Foxf1. 8. The method according to claim 1 , wherein the protein is Foxf2. 9. The method according to claim 1 , wherein the protein is Foxg1. 10. The method according to claim 1 , wherein the nuclear reprogramming substances are Oct3/4, Sox2, and Klf4 proteins, or nucleic acids that encode Oct3/4, Sox2, and Klf4 proteins. 11. The method according to claim 1 , wherein the nuclear reprogramming substances are proteins (i) Oct3/4, (ii) a member of the Sox family selected from the group consisting of Sox1, Sox2, Sox3, Sox15, Sox17 and Sox18, (iii) a member of the Klf family selected from the group consisting of Klf1, Klf2, Klf4, and Klf5, and (iv) a member of the Myc family selected from the group consisting of c-Myc, L-Myc, and n-Myc, or nucleic acids that encode (i)-(iv). 12. The method according to claim 1 , wherein the nuclear reprogramming substances are Oct3/4, Sox2, Nanog, and Lin28 proteins, or nucleic acids that encode Oct3/4, Sox2, Nanog, and Lin28 proteins.

Assignees

Inventors

Classifications

  • Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

  • from adult fibroblasts · CPC title

  • C12N5/0696Primary

    Artificially induced pluripotent stem cells, e.g. iPS · CPC title

  • Oct-3/4 · CPC title

  • Genetically modified cells · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10077429B2 cover?
The present invention provides a method of improving iPS cell establishment efficiency, comprising contacting a protein involved in primitive streak (PrS) formation, preferably Foxh1, or a nucleic acid that encodes the same with a somatic cell in a nuclear reprogramming step. Also provided is a method of producing an iPS cell, comprising contacting the protein involved in PrS formation or a nuc…
Who is the assignee on this patent?
Univ Kyoto
What technology area does this patent fall under?
Primary CPC classification C12N5/0696. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).